PledPharma will present its “first in class” drug candidate PledOx phase III program at the Gastrointestinal (GI) Cancers Symposium, taking place in San Francisco today and tomorrow.
PledOx is developed to provide patients that are treated adjuvantly or for metastatic colorectal cancer, prevention against the nerve damage that can occur in conjunction with chemotherapy treatment.
Nicklas Westerholm, CEO, PledPharma AB”We are proud to have been selected as one of the presenters at ASCO GI. I see presenting the study at one of the world’s most prominent Gastrointestinal Cancer symposiums as a confirmation in the interest in PledOx’s potential and the unmet medical need in this patient population.”
The title of the presentation is: The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN). It will be presented by one of the Coordinating Investigators of the POLAR M study, Prof. Per Pfeiffer from Odense University Hospital in Denmark and M.D., Ph.D. Stefan Carlsson, Chief Medical Officer at PledPharma.